Drug Profile
Axalimogene filolisbac - Ayala Pharmaceuticals
Alternative Names: ADXS HPV; ADXS-11-001; ADXS11-001-vaccine; Anal-cancer-vaccine- Ayala Pharmaceuticals; AXAL; Cervical cancer vaccine - Ayala Pharmaceuticals; Head and neck cancer vaccine - Ayala Pharmaceuticals; Listeria cancer vaccine - Ayala Pharmaceuticals; Listeria monocytogenes vaccine live attenuated - Ayala Pharmaceuticals; Live attenuated listeria monocytogenes vaccine - Ayala Pharmaceuticals; Lm-Listeriolysin-O-fetal liver kinase-1; Lm-LLO-E7; Lm-LLO-E7 vaccine; Lovaxin-C; NSC-752718; RaligizeLatest Information Update: 27 Dec 2023
Price :
$50
*
At a glance
- Originator Advaxis
- Developer Advaxis; Ayala Pharmaceuticals; Brown University Medical School; Cancer Research UK; Gynecologic Oncology Group; Icahn School of Medicine at Mount Sinai; MedImmune
- Class Cancer vaccines; Gene therapies
- Mechanism of Action Gene transference; Human papillomavirus E7 protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cervical cancer
Highest Development Phases
- Phase III Cervical cancer
- Phase II Anal cancer; Oropharyngeal cancer
- Phase I/II Head and neck cancer
- Discontinued Cervical intraepithelial neoplasia
Most Recent Events
- 19 Dec 2023 Advaxis withdrew a phase II trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA and Taiwan, prior to enrolment (NCT02531854)
- 19 Jan 2023 Advaxis has merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals
- 09 Mar 2022 Phase III development is still ongoing for Cervical cancer in Argentina, Brazil, Canada, Chile, Malaysia, Mexico, Poland, Russia, Serbia, South Korea, Spain, Taiwan, USA, Ukraine